Abstract

Current antiretroviral therapy has reduced morbidity and mortality of HIV patients. However, their induced hepatotoxicity constitutes a risk. In this issue, we report a clinical case of fulminant hepatitis, observed in the HIV unit of the hepatogastroenterology department of the General hospital of Loandjili in Pointe-Noire. The patient is a 36-year-old female HIV treated with triple-dug combination antiretroviral therapies (ART) including one antiprotease (ritonavir) and two non-nucleoside reverse transcriptase inhibitors (nevirapine and efavirenz). He developed fulminant hepatitis five years after treatment initiation. He succumbed to the side effects. Although antiretroviral combination therapies are the standard of care for HIV infection, increased vigilance is warranted to early identify this side effect and adjust treatment in order to prevent fatal consequences.

Highlights

  • Combination of antiretroviral therapies (ART) has transformed the natural history of human immunodeficiency virus (HIV) infection with a significant reduction in morbidity and mortality from opportunistic infections

  • We report a clinical case of fulminant hepatitis, observed in the HIV unit of the hepatogastroenterology department of the General hospital of Loandjili in Pointe-Noire

  • The patient is a 36-year-old female HIV treated with triple-dug combination antiretroviral therapies (ART) including one antiprotease and two non-nucleoside reverse transcriptase inhibitors

Read more

Summary

Introduction

Combination of antiretroviral therapies (ART) has transformed the natural history of human immunodeficiency virus (HIV) infection with a significant reduction in morbidity and mortality from opportunistic infections. Some of the ARTs are labelled as hepatotoxic, constituting a potential risk for morbidity and mortality, especially in patients co-infected with the hepatitis B or hepatitis C viruses, and in alcoholic patients.

Bossali et al DOI
Case Report
Physical Examination
Summary
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.